Cold Allergy And Sinus Tablet Market Seen Reaching $39.08B By 2030

The Business Research Company says the global cold allergy and sinus tablet market will rise from $30.4 billion in 2025 to $32 billion in 2026, then grow to $39.08 billion by 2030. The forecast points to steady demand for OTC symptom relief, stronger online pharmacy reach and rising interest in combination, non-drowsy and fast-acting products.

Why it matters: - The cold allergy and sinus tablet market is tied to everyday symptom treatment for colds, allergies and sinus problems. - Rising demand for these products reflects more allergic rhinitis, more seasonal colds and wider use of self-medication. - Growth in the category also signals opportunity for manufacturers, retailers and online pharmacies as consumers look for faster and more targeted relief.

What happened: - The Business Research Company released a 2026 market report on the global cold allergy and sinus tablet market. - The report puts market size at $30.4 billion in 2025 and $32 billion in 2026. - The report forecasts the market will reach $39.08 billion by 2030. - The company estimates a 5.2% CAGR from 2025 to 2026 and a 5.1% CAGR from 2026 to 2030. - The release was dated July 31, 2026, in London. - Download a free sample of the report. - View the full market report.

The details: - Cold allergy and sinus tablets are available over the counter and by prescription. - The tablets typically combine antihistamines, decongestants and pain relievers. - The products are designed to reduce inflammation, ease congestion and lessen discomfort from colds, allergies and sinus issues. - Historic growth has been driven by rising allergic rhinitis cases, more seasonal colds, easy OTC access, self-medication habits and established pharmacy retail channels. - The forecast period is supported by urban pollution, stronger consumer interest in combination therapies, more demand for allergy management products, expanding online pharmacies and continued product reformulation. - Key trends include multi-symptom combination tablets, non-drowsy formulas, fast-acting relief, age-specific dosage forms and extended-release options. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests demand is shifting from basic symptom relief toward more specialized products that fit consumer preferences for convenience, speed and reduced drowsiness. - Faster growth in Asia-Pacific points to the role of urbanization, pollution and improving healthcare access in shaping future sales. - The broader respiratory-health context matters because allergy and sinus products often sit alongside other everyday self-care categories.

What's next: - The market is expected to keep expanding through 2030 as OTC access and online distribution widen. - Product reformulation and age-specific dosing are likely to remain competitive priorities. - Regional growth in Asia-Pacific may narrow the gap with North America if current urbanization and pollution trends continue. - The Business Research Company is offering updated analytical tools in the 2026 edition, including dashboards and scoring models, to help buyers assess opportunities.